Tanshinone IIA arrests cell cycle and induces apoptosis in 786-O human renal cell carcinoma cells

Oncology Letters

Volumn 3, Issue 5, 2012, Pages 1144-1148

  Wei, Xianli ^a,b   Zhou, Lunbin ^b   Hu, Liangyong ^b   Huang, Yaoxiong ^a  

^a JINAN UNIVERSITY   (China)

^b Guangzhou Institute of Measuring and Testing Technology   (China)

Author keywords

Apoptosis; P53; Renal cell carcinoma; Tanshinone IIA

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; CASPASE 3; PROTEIN BAX; PROTEIN P21; PROTEIN P53; TANSHINONE IIA;

APOPTOSIS; ARTICLE; CANCER INHIBITION; CARCINOMA CELL; CELL CYCLE ARREST; CELL VIABILITY; CONTROLLED STUDY; DRUG MECHANISM; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; KIDNEY CARCINOMA; PROTEIN EXPRESSION; RECEPTOR UPREGULATION;

EID: 84863247218     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2012.626     Document Type: Article

References (17)

1. Bird J and Hayter M: A review of the literature on the impact of renal cancer therapy on quality of life. J Clin Nurs 18: 2783-2800, 2009.
2. Kyprianou N, Martikainen P, Davis L, English HF and Isaacs JT: Programmed cell death as a new target for prostatic cancer therapy. Cancer Surv 11: 265-277, 1991.
3. Kyprianou N, Bains AK and Jacobs SC: Induction of apoptosis in androgen-independent human prostate cancer cells undergoing thymineless death. Prostate 25: 66-75, 1994.
4. Jang SI, Kim HJ, Kim YJ, Jeong SI and You YO: Tanshinone IIA inhibits LPS-induced NF-kappaB activation in RAW 264.7 cells: possible involvement of the NIK-IKK, ERK1/2, p38 and JNK pathways. Eur J Pharmacol 542: 1-7, 2006.
5. Li W, Li J, Ashok M, et al: A cardiovascular drug rescues mice from lethal sepsis by selectively attenuating a late-acting proinflammatory mediator, high mobility group box 1. J Immunol 178: 3856-3864, 2007.
6. Lin R, Wang WR, Liu JT, Yang GD and Han CJ: Protective effect of tanshinone IIA on human umbilical vein endothelial cell injured by hydrogen peroxide and its mechanism. J Ethnopharmacol 108: 217-222, 2006.
7. Wang AM, Sha SH, Lesniak W and Schacht J: Tanshinone (Salviae miltiorrhizae extract) preparations attenuate aminoglycoside-induced free radical formation in vitro and ototoxicity in vivo. Antimicrob Agents Chemother 47: 1836-1841, 2003.
8. Wang X, Wei Y, Yuan S, et al: Potential anticancer activity of tanshinone IIA against human breast cancer. Int J Cancer 116: 799-807, 2005.
9. Wang J, Wang X, Jiang S, et al: Growth inhibition and induction of apoptosis and differentiation of tanshinone IIA in human glioma cells. J Neurooncol 82: 11-21, 2007.
10. Chiu TL and Su CC: Tanshinone IIA induces apoptosis in human lung cancer A549 cells through the induction of reactive oxygen species and decreasing the mitochondrial membrane potential. Int J Mol Med 25: 231-236, 2010.
11. Ogryzko VV, Wong P and Howard BH: WAF1 retards S-phase progression primarily by inhibition of cyclin-dependent kinases. Mol Cell Biol 17: 4877-4882, 1997.
12. el-Deiry WS: Regulation of p53 downstream genes. Semin Cancer Biol 8: 345-357, 1998.
13. Sun J, Tan BK, Huang SH, Whiteman M and Zhu YZ: Effects of natural products on ischemic heart diseases and cardiovascular system. Acta Pharmacol Sin 23: 1142-1151, 2002.
14. Lu Q, Zhang P, Zhang X and Chen J: Experimental study of the anti-cancer mechanism of tanshinone IIA against human breast cancer. Int J Mol Med 24: 773-780, 2009.
15. Cao EH, Liu XQ, Wang JJ and Xu NF: Effect of natural antioxidant tanshinone II-A on DNA damage by lipid peroxidation in liver cells. Free Radic Biol Med 20: 801-806, 1996.
16. Yu C, Friday BB, Lai JP, et al: Cytotoxic synergy between the multikinase inhibitor sorafenib and the proteasome inhibitor bortezomib in vitro: induction of apoptosis through Akt and c-Jun NH2-terminal kinase pathways. Mol Cancer Ther 5: 2378-2387, 2006.
17. Müller M, Wilder S, Bannasch D, et al: p53 activates the CD95 (APO-1/Fas) gene in response to DNA damage by anticancer drugs. J Exp Med 188: 2033-2045, 1998.